Ally Financial’s Biogen BIIB Stock Holding History

Ally Financial’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-15,000	Closed	-$4.78M	–	134
2017 Q4	$4.78M	Hold	15,000	–	–	0.92%	32
2017 Q3	$4.7M	Hold	15,000	–	–	0.89%	37
2017 Q2	$4.07M	Hold	15,000	–	–	0.81%	43
2017 Q1	$4.1M	Hold	15,000	–	–	0.92%	34
2016 Q4	$4.25M	Hold	15,000	–	–	0.71%	39
2016 Q3	$4.69M	Hold	15,000	–	–	0.82%	32
2016 Q2	$3.63M	Hold	15,000	–	–	0.61%	52
2016 Q1	$3.9M	Buy	15,000 +4,000	+36%	+$1.06M	0.55%	57
2015 Q4	$3.37M	Buy	11,000 +3,000	+38%	+$862K	0.47%	59
2015 Q3	$2.33M	Buy	8,000 +2,000	+33%	+$660K	0.24%	97
2015 Q2	$2.42M	Buy	+6,000	New	+$2.41M	0.25%	98
2015 Q1	–	Sell	-8,000	Closed	-$2.72M	–	134
2014 Q4	$2.72M	Buy	+8,000	New	+$2.59M	0.3%	108
2014 Q3	–	Sell	-8,000	Closed	-$2.52M	–	133
2014 Q2	$2.52M	Buy	+8,000	New	+$2.41M	0.3%	109

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Ally Financial's BIIB Position: Q1 2018 in Review

Ally Financial sold out of Biogen (BIIB) in Q1 2018, closing a stake of 15,000 shares — an estimated $4.78M sold.

Ally Financial first reported a position in BIIB in Q2 2014 and held it in 13 quarters. The position peaked at $4.78M in Q4 2017. 1,103 funds tracked by Wall St. Rank hold BIIB as of Q1 2018.

Ally Financial reported no remaining Biogen position as of Q1 2018 after selling out during the quarter.
Ally Financial sold 15,000 Biogen shares in Q1 2018, an estimated $4.78M.
Ally Financial first reported a position in Biogen in Q2 2014 and held it in 13 quarters.
Ally Financial's Biogen position peaked at $4.78M in Q4 2017.
1,103 funds tracked by Wall St. Rank held Biogen as of Q1 2018.

Based on Ally Financial's 13F filing for Q1 2018, filed 14 May 2018.